Paul Y. Song
@paulysongmd.bsky.social
Girl Dad, Physician, Biotech CEO, Healthcare Activist
Moderate stage Alzheimer’s disease represents about 30% of all cases and yet no disease modifying therapy has been found and the major focus has been on the early stage/mild cases. Pleased to announce we have been granted Fast Track designation by the U.S. FDA for our efforts using troculeucel.
NKGen Biotech Receives U.S. FDA Fast Track Designation for Troculeucel for the Treatment of Moderate Alzheimer’s Disease
The Fast Track designation accelerates troculeucel’s path to U.S. FDA submission for the treatment of patients with moderate Alzheimer’s disease. NKGen will benefit from increased FDA interactions, en...
nkgenbiotech.com
February 12, 2025 at 8:06 PM
Moderate stage Alzheimer’s disease represents about 30% of all cases and yet no disease modifying therapy has been found and the major focus has been on the early stage/mild cases. Pleased to announce we have been granted Fast Track designation by the U.S. FDA for our efforts using troculeucel.
